RVMD Q3 2024 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$176M

Net Income

-$156M

EPS (Diluted)

$-0.94

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$130M

Free Cash Flow

-$134M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$197M

Stockholders' Equity

$1.6B

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$176M	-$123M	-42.6%
Net Income	-$156M	-$108M	-44.1%